Rituximab vs Sorafenib Tosylate

## Rituximab vs Sorafenib Tosylate: Overview

This comparison examines the pharmacological differences between **Rituximab** and **Sorafenib Tosylate**.

## Mechanism of Action

**Rituximab**: Chimeric anti-CD20 IgG1 monoclonal antibody inducing B-cell depletion via CDC, ADCC, and apoptosis.

## Pharmacokinetics

**Half-life**: Rituximab — 22 days; Sorafenib Tosylate — N/A.

## Chemical Properties

**Type**: Rituximab — Antibody; Sorafenib Tosylate — Small molecule.